Intralesional Acyclovir
Small molecule
Intralesional Acyclovir is one of 12 small molecule programs targeting Plantar Wart. It is currently in development.
1
Indications
2
Total Trials
1
Active Trials
11
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
23 competitors in Plantar Wart
#DrugCompanyPhaseTrials
1Aldara
BBausch Health Americas, Inc.
Approved
Zovirax
BBp Consulting, Inc
Approved
CRYOTHERAPY
AAssistance Publique - Hôpitaux de Paris
Approved
Salicylate
AAssistance Publique - Hôpitaux de Paris
Approved
Inomax
MMallinckrodt
Phase 2
Salicylic Acid
HHadassah Medical Organization
Phase 3
Blenoxane
Bristol-Myers SquibbPreclinical
Potassium Hydroxide
SSohag University
Phase 3
Adrucil
EElorac, Inc.
Preclinical
Xylocaine
CCitius Pharmaceuticals, Inc.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Plantar Wart1 trial
Intralesional Acyclovir Versus Cryotherapy in the Treatment of Plantar Warts. A Randomized Controlled Trial.
Unknown status·—·Phase 2/3·NCT06261684·92 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Intralesional Acyclovir. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Company
- RRiphah International University